Io Therapeutics Archives | Be Korea-savvy
Home / Posts tagged Io Therapeutics
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers

SPRING, Texas, Nov. 08, 2024 (Korea Bizwire) – Io Therapeutics, Inc., presented results from studies done in breast, colorectal, and prostate cancer models with the company’s newest anti-cancer compound IRX5010, an agonist of the retinoic acid nuclear receptor gamma, which was discovered in the company’s oncology drug program. The presentation titled “RAR Gamma Agonist Compounds [...]

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging

SPRING, Texas, Sept. 18, 2024 (Korea Bizwire) – Io Therapeutics, Inc., presented results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration with its clinical stage experimental therapeutic RXR agonist compound IRX4204. The presentation titled “The highly potent and selective third generation RXR nuclear receptor agonist compound IRX4204 has potential [...]

Io Therapeutics, Inc., Presented Today Results from Studies of IRX4204, the Company’s Phase II Clinical Development Stage, Highly Selective RXR Nuclear Receptor Agonist Compound, Supporting Its Potential Use for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Io Therapeutics, Inc., Presented Today Results from Studies of IRX4204, the Company’s Phase II Clinical Development Stage, Highly Selective RXR Nuclear Receptor Agonist Compound, Supporting Its Potential Use for Treatment of Amyotrophic Lateral Sclerosis (ALS)

SPRING, Texas, July 16, 2024 (Korea Bizwire) – Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS). The presentation titled “The RXR Nuclear Receptor Agonist Compound IRX4204 is a [...]

Io Therapeutics, Inc., Presented Data from Studies of IRX4204, the Company’s Phase II Clinical Development Stage, Highly Selective Third Generation RXR Nuclear Receptor Agonist Compound, Supporting Its Potential Use for Prevention and Treatment of Normal Aging-related Neurodegeneration, Parkinson’s Disease, and Alzheimer’s Disease

Io Therapeutics, Inc., Presented Data from Studies of IRX4204, the Company’s Phase II Clinical Development Stage, Highly Selective Third Generation RXR Nuclear Receptor Agonist Compound, Supporting Its Potential Use for Prevention and Treatment of Normal Aging-related Neurodegeneration, Parkinson’s Disease, and Alzheimer’s Disease

SPRING, Texas, Jul. 9 (Korea Bizwire) — Io Therapeutics, Inc., presented today results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease (PD), and Alzheimer’s disease (AD), with its clinical stage experimental therapeutic RXR nuclear receptor agonist compound IRX4204. IRX4204 is a highly potent and highly selective, orally [...]

Io Therapeutics, Inc., Announces Presentation of Data on Induction of Tumor Growth Inhibiting Anti-cancer Immune Responses in Multiple Types of Cancers by a IRX5010, a Novel Retinoic Acid Nuclear Receptor Agonist Compound

Io Therapeutics, Inc., Announces Presentation of Data on Induction of Tumor Growth Inhibiting Anti-cancer Immune Responses in Multiple Types of Cancers by a IRX5010, a Novel Retinoic Acid Nuclear Receptor Agonist Compound

SPRING, Texas, Jul. 8 (Korea Bizwire) — Io Therapeutics, Inc., presented today results from studies done in breast, lung, colorectal, and prostate cancer models with the company’s newest anti-cancer compound IRX5010, an agonist of retinoic acid nuclear receptor gamma which was discovered in the company’s oncology drug program. The presentation titled “RAR Gamma Agonist Compounds [...]

Io Therapeutics, Inc., Announces Publication of Data on a Novel Compound Promoting Anti-Cancer Immune Responses

Io Therapeutics, Inc., Announces Publication of Data on a Novel Compound Promoting Anti-Cancer Immune Responses

SPRING, Texas, Sept. 12, 2023 (Korea Bizwire) – Io Therapeutics, Inc., announced today the publication in Scientific Reports – Nature Publishing Group, of results from studies done with the company’s novel anti-cancer compound IRX4647, an agonist of the retinoic acid nuclear receptor gamma, discovered in the company’s oncology drug program. The paper, titled “A novel retinoic acid [...]